Advanced search
1 file | 698.88 KB

BEV-IP: perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis

(2015) BMC CANCER. 15.
Author
Organization
Abstract
Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC). However, even after optimal cytoreduction, systemic and locoregional recurrence are common. Perioperative chemotherapy with bevacizumab (BEV) may improve the outcome of these patients. Methods/Design: The BEV-IP study is a phase II, single-arm, open-label study aimed at patients with colorectal or appendiceal adenocarcinoma with synchronous or metachronous PC. This study evaluates whether perioperative chemotherapy including BEV in combination with CRS and oxaliplatin-based IPC results in acceptable morbidity and mortality (primary composite endpoint). Secondary endpoints are treatment completion rate, chemotherapy-related toxicity, pathological response, progression free survival, and overall survival. Discussion: The BEV-IP trial is the first prospective assessment of the safety and efficacy of perioperative chemotherapy combined with anti-angiogenic treatment in patients undergoing CRS and IPC for colorectal peritoneal metastases.
Keywords
RANDOMIZED-TRIAL, PLUS BEVACIZUMAB, LIVER METASTASES, MALIGNANT ASCITES, SYSTEMIC CHEMOTHERAPY, NEOADJUVANT CHEMOTHERAPY, PERITONEAL CARCINOMATOSIS, INTERSTITIAL FLUID PRESSURE, Peritoneal carcinomatosis, Perioperative chemotherapy, HIPEC, OVARIAN-CANCER, SURGERY, Cytoreductive surgery, Bevacizumab, Colorectal cancer

Downloads

  • BEV IP Perioperative chemotherapy with bevacizumab in patients undergoing.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 698.88 KB

Citation

Please use this url to cite or link to this publication:

Chicago
WILLAERT, WOUTER, Kurt Van Der Speeten, Gabriel Liberale, and Wim Ceelen. 2015. “BEV-IP: Perioperative Chemotherapy with Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis.” Bmc Cancer 15.
APA
WILLAERT, W., Van Der Speeten, K., Liberale, G., & Ceelen, W. (2015). BEV-IP: perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis. BMC CANCER, 15.
Vancouver
1.
WILLAERT W, Van Der Speeten K, Liberale G, Ceelen W. BEV-IP: perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis. BMC CANCER. 2015;15.
MLA
WILLAERT, WOUTER, Kurt Van Der Speeten, Gabriel Liberale, et al. “BEV-IP: Perioperative Chemotherapy with Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis.” BMC CANCER 15 (2015): n. pag. Print.
@article{7036724,
  abstract     = {Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC). However, even after optimal cytoreduction, systemic and locoregional recurrence are common. Perioperative chemotherapy with bevacizumab (BEV) may improve the outcome of these patients. 
Methods/Design: The BEV-IP study is a phase II, single-arm, open-label study aimed at patients with colorectal or appendiceal adenocarcinoma with synchronous or metachronous PC. This study evaluates whether perioperative chemotherapy including BEV in combination with CRS and oxaliplatin-based IPC results in acceptable morbidity and mortality (primary composite endpoint). Secondary endpoints are treatment completion rate, chemotherapy-related toxicity, pathological response, progression free survival, and overall survival. 
Discussion: The BEV-IP trial is the first prospective assessment of the safety and efficacy of perioperative chemotherapy combined with anti-angiogenic treatment in patients undergoing CRS and IPC for colorectal peritoneal metastases.},
  articleno    = {980},
  author       = {Willaert, Wouter and Van Der Speeten, Kurt and Liberale, Gabriel and Ceelen, Wim},
  issn         = {1471-2407},
  journal      = {BMC CANCER},
  keyword      = {RANDOMIZED-TRIAL,PLUS BEVACIZUMAB,LIVER METASTASES,MALIGNANT ASCITES,SYSTEMIC CHEMOTHERAPY,NEOADJUVANT CHEMOTHERAPY,PERITONEAL CARCINOMATOSIS,INTERSTITIAL FLUID PRESSURE,Peritoneal carcinomatosis,Perioperative chemotherapy,HIPEC,OVARIAN-CANCER,SURGERY,Cytoreductive surgery,Bevacizumab,Colorectal cancer},
  language     = {eng},
  pages        = {8},
  title        = {BEV-IP: perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis},
  url          = {http://dx.doi.org/10.1186/s12885-015-1954-x},
  volume       = {15},
  year         = {2015},
}

Altmetric
View in Altmetric
Web of Science
Times cited: